معرفی
Dr. Catherine Carmichael is a group leader at the Centre for Cancer Research, Hudson Institute of Medical Research, and an adjunct Senior Research Fellow in the School of Clinical Sciences at Monash University. Her research is centered on understanding the molecular mechanisms underlying Acute Myeloid Leukemia (AML) and developing novel therapeutic strategies for this aggressive malignancy.
Her research interests include Acute Myeloid Leukemia, hematopoiesis, hematopoietic stem cells, molecular genetics, and transcriptional regulation. She employs advanced models such as patient-derived xenografts and investigates epigenetic mechanisms involving EMT transcription factors like ZEB1, ZEB2, and SNAI1. Her work contributes to the United Nations Sustainable Development Goals, particularly in health and well-being.
The recent articles highlight a strong focus on genetic and epigenetic drivers of AML, with studies on RUNX1 mutations, master transcription factors in erythroleukemia, and the role of SNAI1-LSD1 interaction in leukemogenesis. These works reflect a consistent theme in targeting molecular pathways for therapeutic discovery in myeloid malignancies.
- Adjunct Senior Research Fellow, School of Clinical Sciences, Monash University
- Group Leader, Leukaemia Modelling and Therapeutic Discovery, Hudson Institute
Dr. Carmichael has secured competitive research funding, including from the NHMRC, and leads multiple active projects such as the development of broadly applicable therapeutic strategies for AML. She is currently accepting PhD and Honours students, indicating active supervision and mentorship. She collaborates with national and international researchers, contributing to large-scale genomic and translational studies.
She is affiliated with the Leukaemia Modelling and Therapeutic Discovery group at the Hudson Institute, which focuses on preclinical modeling and drug discovery for AML. The team integrates genomics, epigenetics, and functional studies to identify and validate therapeutic targets.
